Elite Diagnostic Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Harvey Levers

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

CEO

Harvey Levers

no data

Tenure

Mr. Harvey Levers is Chief Executive Officer of Elite Diagnostic Limited since July 01, 2022 and serves as its Executive Director. Mr. Levers. gained extensive senior and executive management experience in...

Elite Diagnostic Management

Management criteria checks 0/4

Key information

Recent management updates

Elite Diagnostic Limited Announces CEO Changes, Effective November 30, 2024

Elite Diagnostic Limited Announces CEO Changes, Effective November 30, 2024

Elite Diagnostic Limited Announces Board Changes

No independent directors

No independent directors

Elite Diagnostic Limited, Annual General Meeting, Dec 14, 2020

Recent updates

Elite Diagnostic Limited Announces CEO Changes, Effective November 30, 2024

Elite Diagnostic Limited Announces CEO Changes, Effective November 30, 2024

First quarter 2025 earnings released: JA$0.03 loss per share (vs JA$0.016 loss in 1Q 2024)

Investor sentiment improves as stock rises 15%

Full year 2024 earnings released: EPS: JA$0.074 (vs JA$0.038 in FY 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Full year 2024 earnings released: EPS: JA$0.09 (vs JA$0.038 in FY 2023)

Second quarter 2024 earnings released: JA$0.03 loss per share (vs JA$0.021 loss in 2Q 2023)

Elite Diagnostic Limited Announces Board Changes

First quarter 2024 earnings released: JA$0.02 loss per share (vs JA$0.016 profit in 1Q 2023)

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: JA$0.038 (vs JA$0.14 in FY 2022)

Full year 2023 earnings released: EPS: JA$0.008 (vs JA$0.14 in FY 2022)

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 28%

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: JA$0.02 (vs JA$0.08 in 3Q 2022)

Investor sentiment deteriorates as stock falls 21%

Second quarter 2023 earnings released: JA$0.02 loss per share (vs JA$0.021 profit in 2Q 2022)

Investor sentiment deteriorated over the past week

No independent directors

Investor sentiment deteriorated over the past week

No independent directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: JA$0.001 loss per share (vs JA$0.029 loss in 1Q 2021)

Full year 2021 earnings released: EPS JA$0.005 (vs JA$0.024 in FY 2020)

Full year 2021 earnings released: EPS JA$0.002 (vs JA$0.024 in FY 2020)

Third quarter 2021 earnings released: EPS JA$0.01 (vs JA$0.006 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JA$0.01 (vs JA$0.013 in 2Q 2020)

New 90-day low: JA$2.71

Elite Diagnostic Limited, Annual General Meeting, Dec 14, 2020

First quarter 2021 earnings released: JA$0.03 loss per share

Full year earnings released - EPS JA$0.024

New 90-day low - JA$3.00

Full year earnings released - EPS JA$0.02

New 90-day low - JA$3.11

CEO

Tenure